A public meeting and hearing of the
Utah Department of Health
State Medicaid Drug Utilization Review Board
Thursday September 10th, 2015
Public meeting 7:00 a.m. to 8:00 a.m.
Board Evaluation of Prior Authorization Requests 8:00 a.m. to 8:30 a.m.
Cannon Health Building - Room 125
Agenda
Welcome - Tony Dalpiaz, Pharm.D., Board Chair
Housekeeping - Robyn Seely, Pharm.D.
Approval of August Public Meeting Minutes - Tony Dalpiaz, Pharm.D., Board Chair
9-Month Review: Disease-Modifying Antirheumatic Drugs - Robyn Seely, Pharm.D.
Cyctic Fibrosis Transmembrane Regulators: Orkambi (lumacaftor and Ivacaftor) and Kalydeco (ivacaftor) -Joanita Lake, B.Pharm, MSc EBHC (Oxon)
Public Comment
Intermountain Cystic Fibrosis Center at University of Utah Hospital
Letter from the Cystic Fibrosis Foundation
Vertex
Board Discussion
Board Action
Vote to close the meeting - Tony Dalpiaz, Pharm.D., Board Chair
Board Meeting Agendas:
Visitors may address the Board as time permits. To be added to the agenda, at least 7 days advance notice must be given. Please contact Robyn Seely, Pharm.D. at rmseely@utah.gov (preferred) or 801-538-6079. DUR Board Meeting Agendas are posted at least 14 days in advance, at http://www.utah.gov/pmn/index.html, in the Salt Lake Tribune, in the Deseret News and at the meeting location (Department of Health Cannon Building). Upcoming meetings will be held in the Cannon Health Building, beginning at 7:00 a.m., 10/08/2015, 11/12/2015, 12/10/2015, 01/14/2016, 02/11/2016, 03/11/2016, and 04/08/2016.
This is a proposed agenda. The actual meeting time may not allow for discussion of all proposed items. Agenda items not discussed in the meeting may be addressed during the next regularly scheduled meeting or during a future Board meeting. Business carried forward may be discussed at the next scheduled meeting(s). All data presented at DUR Board meetings reference gross paid claims from Utah Medicaid's data warehouse. Final year-end dollar and unit amounts may be different due to ledger adjustment.
The Purpose of the Drug Utilization Review Board:
Utah Medicaid's Pharmacy Department manages both a Drug Utilization Review (DUR) Board and a Pharmacy and Therapeutics (P&T) Committee. Provisions for the DUR Board are found in the Utah Administrative Code, Rule R414-60A. The P&T Committee is a sub-committee of the DUR Board and is provided for in the Utah Administrative Code, Rule R414-60B. The DUR Board's goal is to ensure appropriate, medically necessary use of medications while preventing fraud, waste and abuse. To accomplish this, the DUR Board may recommend clinical prior authorization criteria for a medication. The P&T Committee's goals are to establish the safety and efficacy of therapeutic classes of medications for possible inclusion on Utah Medicaid's Preferred Drug List.
Notice of Special Accommodations (ADA)
NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Robyn Seely at 801-538-6841.